Glimepiride: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 55, Issue 4, 1998, Pages 563-584

  Langtry, Heather D ^a,b   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; PROPRANOLOL; SULFONAMIDE; SULFONYLUREA;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; VERTIGO;

BLOOD GLUCOSE; CONTROLLED CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; SULFONYLUREA COMPOUNDS; TISSUE DISTRIBUTION;

EID: 0031955215     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855040-00007     Document Type: Article

References (73)

1. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at β-cells. Horm Metab Res 1996 Sep; 28: 464-8
2. Muller G, Hartz D, Pünter J, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta Biomembr 1994 May 11; 1191: 267-77
3. 3H]glimepiride. Biochim Biophys Acta 1994 May 11; 1191: 278-90
4. + channels and stimulation of insulin secretion by the sulfonylurea. glimepiride, in relation to its membrane binding in pancreatic islets. Pharmacology 1994 Aug; 49: 105-11
5. Marynissen G, Smets G, Klöppel G, et al. Internalization of glimepiride and glibenclamide in the pancreatic B-cell. Acta Diabetol 1992 Nov; 29: 113-4
6. Lebrum P, Malaisse WJ. Cationic and secretory effects of glimepiride and glibenclamide in perifused rat islets. Pharmacol Toxicol 1992 May; 70: 357-60
7. Muller G, Korndörfer A, Kornak U, et al. Porin proteins in mitochondria from rat pancreatic islet cells and white adipocytes: identification and regulation of hexokinase binding by the sulfonylurea glimepiride. Arch Biochem Biophys 1994 Jan; 308: 8-23
8. Porzio O, Magnaterra R, Marlier LNJL, et al. Glimepiride enhances glucokinase and GLUT2 mRNA expression in insulinoma cells [abstract]. Diabetologia 1996 Aug; 39 Suppl. 1: A30
9. Gregorio F, Ambrosi F, Cristallini S, et al. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetol 1996 Mar; 33: 25-9
10. Leclercq-Meyer V, Akkan AG, Marchand J, et al. Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas. Biochem Pharmacol 1991 Sep 27; 42: 1634-7
11. Wernicke-Panten K, Haupt E, Pfeiffer C, et al. Early onset of pharmacodynamic effects of glimepiride in type II diabetic patients [abstract]. Diabetologia 1994; 37 Suppl. 1: A163
12. Badian M, Korn A, Lehr K-H, et al. Pharmacokinetics and pharmacodynamics of the hydroxy-metabolite of glimepiride (Amaryl®) after intravenous administration. Drug Metabol Drug Interact 1996; 13 (1): 69-85
13. Pfeiffer C, Willms B, Talaulicar M, et al. Effects of glimepiride and glibenclamide on the blood glucose profile of type II diabetic patients [abstract]. 15th Int Diab Fed Congr 1994; 416
14. Herron JM. Dose-response study of glimepiride (HOE 490) in patients with noninsulin-dependent diabetes mellitus. Protocol 104. Hoechst-Roussel Pharmaceuticals Inc. (Data on file)
15. van der Wal PS, Draeger KE, van Iperen AM, et al. Beta cell response to oral glimepiride administration during and following a hyperelycaemic clamp in NIDDM patients. Diabetic Med 1997 Jul; 4: 556-63
16. Clark HE, Matthews DR. The effect of glimepiride on pancreatic β-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996 Sep; 28: 445-50
17. Korytkowski M, Reid L, Thomas A. Effect of glimepiride on insulin action and secretion in NIDDM [abstract]. Diabetes 1994; 43 Suppl. 1: 219A
18. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996 Sep; 28: 451-5
19. Rosskamp R, Herz M. Effect of the time of ingestion of the sulfonylurea glimepiride on the daily blood glucose profile in NIDDM patients [abstract]. 15th Int Diab Fed Congr 1994; 416
20. Sato J, Ohsawa I, Oshida Y, et al. Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabetes Res Clin Pract 1993 Oct-Nov; 22: 3-9
21. Kawamori R, Morishima T, Kubota M, et al. Influence of oral sulfonylurea agents on hepatic glucose uptake. Diabetes Res Clin Pract 1995 Aug; 28 Suppl.: S109-13
22. Müller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995 Aug; 28 Suppl.: S115-37
23. Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 1996 Sep; 28: 469-87
24. Muller G, Wied S, Wetekam EM, et al. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 1994 Aug 30; 48: 985-96
25. Müller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993 Dec; 42: 1852-67
26. Bahr M, von Holtey M, Müller G, et al. Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 1995 Jun; 136: 2547-53
27. Eckel J. Direct effects of glimepiride on protein expression of cardiac glucose transporters. Horm Metab Res 1996 Sep; 28: 508-11
28. Takada Y, Takata Y, Iwanishi M, et al. Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse. Eur J Pharmacol 1996 Jul 18; 308: 205-10
29. Bijlstra PJ, Lutterman JA, Russel FGM, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996 Sep; 39: 1083-90
30. Zhang H, Cook D. Antagonism of eicosanoid-induced contraction of rat aorta by sulphonylureas. Pharmacology 1994 Sep; 49: 173-83
31. Geisen K, Végh A, Krause E, et al. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996 Sep; 28: 496-507
32. Ballagi-Pordány G, Németh M, Aranyi Z, et al. Effect of glimepiride on the electrical activity of isolated rabbit heart muscle. Arzneimittel Forschung 1992 Feb; 42: 111-3
33. Lehr KH, Damm P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. J Chromatogr 1990 Apr 6; 526: 497-505
34. Badian M, Korn A, Lehr K-H, et al. Absolute bioavailability of glimepiride (Amaryl®) after oral administration. Drug Metabol Drug Interact 1994; 11 (4): 331-9
35. Kaku K, Yaga K, Inoue Y, et al. Study on pharmacokinetics and pharmacodynamics of HOE490. Seven days multiple administration study [in Japanese]. Rinsho Iyaku 1993; 9 (4): 795-807
36. Malerczyk V, Badian M, Korn A, et al. Dose linearity assessment of glimepiride (Amaryl®) tablets in healthy volunteers. Drug Metabol Drug Interact 1994; 11 (4): 341-57
37. Nakashima M, Kanamaru M, Ujita S, et al. Safety, pharmacodynamics and pharmacokinetics of glimepiride (HOE490) after single oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1993; 9 (3): 503-22
38. Ratheiser K, Korn A, Waldhäusl W, et al. Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. Arzneimittel Forschung 1993 Aug; 43: 856-8
39. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996 Sep; 28: 434-9
40. Profozic V, Mrzljak V, Rosenkranz B, et al. Pharmacokinetics of glimepiride in kidney disease [abstract]. Diabetes 1991 May; 40 Suppl. 1: 343A
41. Hoechst-Roussel Pharmaceuticals. Amaryl® glimepiride tablets prescribing information. Hoechst-Roussel Pharmaceuticals. Division of Hoechst Marion Roussel Inc, Kansas City, MO 64137 USA
42. Shukla UA, Sha X, Lehr KH, et al. Single dose and steady-state pharmacokinetics of glimepiride, a new oral sulfonylurea, in patients with non-insulin-dependent diabetes mellitus [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S-368
43. Yumazaki H, Tabata S. Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats. Arzneimittel Forschung 1993 Dec; 43: 1317-21
44. Stalker DJ, Viveash DM, Ogrinc FG. The effect of age and dosing regimen on the pharmacokinetics of glimepiride in subjects with noninsulin dependent diabetes mellitus [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S-339
45. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996 Dec; 39: 1617-24
46. Schaaf LJ, Sisson TA, Dietz AJ, et al. Influence of multiple dose glimepiride on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy volunteers [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S-359
47. Schneider J, Chaikin P. Glimepiride safety: results of placebo-controlled, dose-regimen, and active-controlled trials. Post-grad Med 1997 Jun; Special Report: 33-44
48. Schaaf LJ, Welshman IR, Viveash DM, et al. The effects of cimetidine and ranitidine on glimepiride pharmacokinetics and pharmacodynamics in normal subjects [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S-360
49. Goldberg RB, Holvey SM, Schneider J, et al. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996 Aug; 19: 849-56
50. Kaneko T, Kaku K, Sakamoto N, et al. Study on minimum effective dose of glimepiride (HOE490) for non-insulin dependent diabetes mellitus patients. Multi center double blind trial compared to placebo [in Japanese]. Rinsho Iyaku 1993; 9 (4): 827-48
51. Clark Jr CM. Goldberg RB. Glimepiride dosing and efficacy: results of placebo-controlled, dose-regimen, and active-controlled trials. Postgrad Med 1997 Jun Special Report: 45-56
52. Hoechst-Roussel Pharmaceuticals Inc. USA. A placebo controlled, dose-titration study of HOE490 in patients with non-insulin-dependent diabetes mellitus (NIDDM). Protocol 202. (Data on file)
53. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996 Nov; 19: 1194-9
54. Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 1997 Jun; 31: 671-6
55. Charpentier G. Comparative double-blind study of the effective dosages of glimepiride and gliclazide in non-insulin-dependent diabetics. Protocol 301F. Laboratoires Hoechst, France. (Data on file)
56. Dills DG, Schneider J, Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996 Sep; 28: 426-9
57. Draeger KE, Wernicke-Panten K, Lomp H-J, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 1996 Sep; 28: 419-25
58. Draeger E, Rosskamp R, Lomp H-J. et al. Multicenter clinical trial to study the effects of glimepiride during long-term treatment of type II diabetic patients: double-blind, parallel-group comparison of glimepiride and Euglucon N (micronised glibenclamide). Protocol 311. Hoechst AG. (Data on file)
59. Wernicke-Panten K, Rosskamp R, Schaler E, et al. Follow-up study to multinational clinical trial to study the effects of glimepiride during long-term treatment of type II diabetic patients: double-blind, parallel-group comparison of glimepiride and Euglucon N (micronised glibenclamide). Protocol 312. Hoechst AG. (Data on file)
60. Riddle MC, Schneider J, Glimepiride Combination Group. Efficacy and safety of glimepiride with evening insulin versus insulin alone when sulfonylureas alone fail. Hoechst-Marion-Roussel Pharmaceuticals Inc. (Data on file)
61. Riddle M, Schneider J, Glimepiride CG. Glimepiride (HOE490) combined with insulin tor NIDDM secondary failures to sulfonylurea monotherapy: results of a multicenter trial [abstract]. 15th Int Diab Fed Congr 1994: 418
62. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996 Sep; 28: 413-8
63. Heine RJ. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: part II - 'the cons'. Horm Metab Res 1996; 28: 522-6
64. HMR's Amaryl launched in UK. Scrip 1997 Aug 12 (2257): 19
65. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 Jul; 20 (7): 1183-97
66. Watkins PJ. Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. J R Coll Physicians Lond 1993 Jul; 27: 259-66
67. Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm Metab Res 1996 Sep; 28: 430-3
68. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996 Jan; 19 Suppl. 1: S54-61
69. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis. Diabetes Metab Rev 1995 Sep; 11 Suppl. 1: S57-62
70. Harrower ADB. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diab Comp 1994 Oct-Dec; 8: 201-3
71. Johnson JL, Wolf SL, Kahadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a metaanalysis of the randomized placebo-controlled trials. Arch Intern Med 1996 Feb 12: 156: 259-64
72. Rosenstock J. Combination glimepiride-insulin 70/30 therapy for NIDDM. Postgrad Med 1997 Jun Special Report: 26-32
73. Group LC. Sulfonylureas in NIDDM. Diabetes Care 1992 Jun; 15 (6): 737-54